Heart failure & cardiomyopathiesRandomised controlled trial
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- Randomised controlled trial
- phase 3
- double-blind
- placebo-controlled
Authors' conclusion
Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than among those who received placebo.
Study context
- Population
- Chronic HF (NYHA class II, III, or IV), EF <45%, recently hospitalized or received intravenous diuretic therapy
- Participants
- 5,050 participants
- Comparison
- Vericiguat vs placebo, added to guideline-based medical therapy
- Vericiguatn = 2,526
- Placebon = 2,524reference
- Primary endpoint
- Composite of:
- CV death
- First hospitalization for HF
- Follow-up
- Median 10.8 months
Primary result
As reported in the abstract
Hazard ratio
0.90
95% CI 0.82–0.98
P = 0.02
Events by treatment group
Vericiguat vs Placebo
HR 0.90 (95% CI 0.82–0.98); P = 0.02
Further findings
| Outcome | Vericiguat | Placebo | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Hospitalization for HF | 27.4% | 29.6% | 0.90 (0.81–1.00) | ||
| CV death | 16.4% | 17.5% | 0.93 (0.81–1.06) | ||
| Death from any cause or hospitalization for HF | 37.9% | 40.9% | 0.90 (0.83–0.98) | P = 0.02 | |
| 0.512Hazard ratio (log scale) |
Safety
Symptomatic hypotension
P = 0.12
Syncope
P = 0.30
Original publication
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. Published 28 March 2020. doi:10.1056/nejmoa1915928
Summarised from the published abstract; every number is checked against it